GlassScriptPhysician profile
Lauren E Regoli
NPI 1760102016
$2,269.22
in general payments reported to CMS, 2019-2025
26 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $309 · 2023: $1,548 · 2024: $24.79 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.89 | 2022-2023 | |
| Novo Nordisk INC | $235.85 | 2022-2023 | Rybelsus, Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $168.49 | 2023-2025 | Uptravi, Opsumit |
| Lilly USA, LLC | $149.91 | 2022-2023 | Trulicity, Mounjaro, Jardiance |
| Scpharmaceuticals INC. | $110.31 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.14 | 2024-2025 | Lifevest |
| Pfizer INC. | $105.10 | 2022-2023 | |
| Glaxosmithkline, LLC. | $95.43 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.33 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $82.31 | 2022-2025 | Farxiga |
| Amgen INC. | $75.78 | 2023 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $69.43 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $59.41 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $50.37 | 2023 | Trintellix |
| Amarin Pharma, INC. | $43.90 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.00 | 2022-2023 | Veozah |
| Medtronic, INC. | $38.72 | 2023 | Inpen Smart Insulin Delivery System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.33 | 2023 | Xifaxan |
| Exact Sciences Corporation | $29.16 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $28.25 | 2022-2023 | |
| Lundbeck LLC | $28.00 | 2022-2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $25.64 | 2023 | Soliris |
| Edwards Lifesciences Corporation | $22.83 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi Pasteur INC. | $22.18 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.84 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.62 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Regoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.